abstract-dark-graphic-banner--3
Thursday November 13th  |  11:30 AM ET / 8:30 AM PT

Rethinking Life Sciences
Commercialization for 2026:

What’s Working, What’s Not, and What’s Next
– Learnings from 140 Industry Leaders

Register now

We asked 140 life sciences leaders across the industry to share what truly makes or breaks commercialization today.

They shared common challenges like fragmented data, limited visibility and customer insight, unclear ownership, and the struggle to move and adapt fast enough amid faster market dynamics and the pace of AI. We also heard clear differences in how large pharma and emerging biopharma approach commercialization—and opportunities for each to learn from the other.

Beghou_Coworkers at Meeting_009

Join us as we share a preview of the full report and unpack what’s working, what’s not, and what’s next.

We’ll share findings from our Commercialization That Works research and hear from industry leaders and Beghou experts about how organizations are adapting for 2026.

What you’ll learn:

  • Success drivers and barriers: How teams are “making it work with less” — and the unintended pitfalls and learnings across commercial operations, data, access, and engagement
  • Timing and planning learnings: How early is "early enough" and how to stay agile once plans are in motion
  • “What works” across company sizes: What large and emerging biopharma can learn from each other’s playbooks
  • Real-world case studies: Case studies and practical takeaways for building sustainable commercial success

Register to receive the recording, presentation slides, and full report even if you can’t make it to the live session.

Speakers

Amit Grover

Amit Grover

AVP, Commercial Excellence, Stemline Therapeutics, 
a Menarini Company

Hasini

Hasini Jayatilaka

Associate director oncology – global commercial strategy & operations, Gilead

Melissa McDevitt-8605_SQUARE-1

Melissa McDevitt

Partner, Beghou

Marcos Mendell

Marcos Mendell

Partner, Beghou